WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406805

CAS#: 211555-05-4

Description: WHI-P97 is a JAK3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 microM in EGFR kinase inhibition assays. WHI-P97 effectively inhibited the in vitro invasiveness of EGFR-positive human cancer cells in a concentration-dependent manner.

Price and Availability




WHI-P97 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406805
Name: WHI-P97
CAS#: 211555-05-4
Chemical Formula: C16H13Br2N3O3
Exact Mass: 452.9324
Molecular Weight: 455.106
Elemental Analysis: C, 42.23; H, 2.88; Br, 35.11; N, 9.23; O, 10.55

Synonym: WHI-P97; WHI-P 97; WHI-P 97; WHIP 97; WHIP97; WHIP-97

IUPAC/Chemical Name: 2,6-dibromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol


InChi Code: InChI=1S/C16H13Br2N3O3/c1-23-13-5-9-12(6-14(13)24-2)19-7-20-16(9)21-8-3-10(17)15(22)11(18)4-8/h3-7,22H,1-2H3,(H,19,20,21)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Ji KA, Yang MS, Jou I, Shong MH, Joe EH. Thrombin induces expression of cytokine-induced SH2 protein (CIS) in rat brain astrocytes: involvement of phospholipase A2, cyclooxygenase, and lipoxygenase. Glia. 2004 Nov 1;48(2):102-11. PubMed PMID: 15378659.

2: Wong WS, Leong KP. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta. 2004 Mar 11;1697(1-2):53-69. Review. PubMed PMID: 15023350.

3: Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, Navara CS, Narla RK. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets. 2001 May;1(1):59-71. Review. PubMed PMID: 12188892.

4: Sudbeck EA, Ghosh S, Liu XP, Zheng Y, Myers DE, Uckun FM. Tyrosine kinase inhibitors against EGF receptor-positive malignancies. Methods Mol Biol. 2001;166:193-218. Review. PubMed PMID: 11217368.

5: Malaviya R, Chen CL, Navara C, Malaviya R, Liu XP, Keenan M, Waurzyniak B, Uckun FM. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec;295(3):912-26. PubMed PMID: 11082424.

6: Ghosh S, Narla RK, Zheng Y, Liu XP, Jun X, Mao C, Sudbeck EA, Uckun FM. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents. Anticancer Drug Des. 1999 Oct;14(5):403-10. PubMed PMID: 10766295.

7: Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, Uckun FM. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5(6):1569-82. PubMed PMID: 10389946.